Takeda Adds Exelixis Arrow To Oncology Quiver

Takeda's acquisition of Japanese rights to Exelixis' lead product fills a gap in the oncology portfolio while adding another piece to the US company's global licensing jigsaw.

Kidneys

Takeda Pharmaceutical Co. Ltd. has paid $50m upfront to acquire exclusive commercialization rights in Japan to Exelixis Inc.'s oral small molecule cancer drug cabozantinib, for all potential indications including advanced renal cell carcinoma (RCC).

South San Francisco-based Exelixis is also eligible for further development, regulatory and first sales milestone payments totaling up to $95m...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip